Nektar Therapeutics could join the growing list of biotechs opting for a takeover—if a Bloomberg report that it is exploring strategic options for the business proves to be true.
The newswire says the San Francisco-based company is looking at a sale of the business as well as partnerships, citing people with knowledge of the matter. The value of the company has been rising steadily over the last few months with its cap currently around the $15 billion mark—a level which Bloomberg suggests could make some suitors think twice given risks in its pipeline.
If Nektar does attract interest from suitors it could add to a bumper crop of deals starting the year for biotech M&A. More than $25 billion of industry deals have already been announced, headed by Sanofi’s $11.6 billion play for Biovarativ and Celgene’s $9 billion buyout of Juno Therapeutics.
Nektar, which combines drug delivery projects with novel therapies R&D, has had mixed fortunes over the last few months. It saw regulatory setbacks for two inhaled antibiotic programs and cancer therapy Onzeald (etirinotecan pegol) in Europe, but also positive pipeline progress and new partnerships with Eli Lilly and Takeda.
Much of the recent momentum behind the stock seems to have come from NKTR-214, an immuno-oncology candidate that posted encouraging clinical data in the phase 1 PIVOT-02 trial alongside Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) at the Society for Immunotherapy of Cancer (SITC) conference last November.
The drug is a CD122-biased agonist designed to stimulate the patient’s own immune system to fight cancer, specifically by boosting cancer-killing T cells and natural killer (NK) cell populations. In the wake of the SITC data analysts at Canaccord and JPMorgan raised their price targets for the stock on what they saw as greater chances of approval in lung cancer, a particularly lucrative market for immuno-oncology therapies.
Nektar is also testing the drug in clinical trials as a monotherapy and is combination with two other checkpoint inhibitors, Merck & Co.’s Keytruda (pembrolizumab) and Roche’s Tecentriq (atezolizumab). And last year it formed an alliance with Takeda to pair NKTR-214 with up to five of the Japanese pharma’s oncology compounds.
Also generating some buzz are Nektar’s chronic pain treatment NKTR-181, a mu opioid drug which hit the mark in a phase 3 trial in chronic back pain last year, and UCB/Biogen-partnered anti-CD40 candidate dapirolizumab pegol which is in phase 2 for the inflammatory disease systemic lupus erythematosus (SLE).
By Phil Taylor
Source: Fierce Biotech
Though Galapagos has undergone plenty of staff shake-ups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following his arrival at the biotech from Johnson & Johnson in early 2022.
The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.
A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing juggernaut Lonza is attempting to reassure the market that an industry stabilization is on the horizon.
